Skip to main content
main-content

01.12.2018 | Research article | Ausgabe 1/2018 Open Access

BMC Endocrine Disorders 1/2018

Assisted reproductive techniques with congenital hypogonadotropic hypogonadism patients: a systematic review and meta-analysis

Zeitschrift:
BMC Endocrine Disorders > Ausgabe 1/2018
Autoren:
Yinjie Gao, Bingqing Yu, Jiangfeng Mao, Xi Wang, Min Nie, Xueyan Wu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1186/​s12902-018-0313-8) contains supplementary material, which is available to authorized users.
Abbreviations
ART
Assisted reproductive techniques
CHH
Congenital hypogonadotropic hypogonadism
ET
Embryo transfer
GnRH
Gonadotropin releasing hormone
hCG
Human chorionic gonadotropin
hMG
Human menopausal gonadotropin
HRT
Hormonal replacement therapy
ICSI
Intracytoplasmic sperm injection
IUI
Intrauterine insemination
IVF-ET
In vitro fertilization-embryo transplantation
OHSS
Ovarian hyperstimulation syndrome
PR
Pregnancy rate
TEST
Testicular sperm extraction

Background

Congenital hypogonadotropic hypogonadism (CHH) is a disorder characterized by lacking of puberty and infertility, with low levels of circulating gonadotropins and sex steroids. Two pathogenesis mechanisms exist for CHH. One is the reduced secretion of gonadotropin releasing hormone (GnRH) from the hypothalamus, and the other is the GnRH receptor defect in the pituitary. The incidence of CHH is approximately 1/10000–1/86000 [ 1], and the ratio of male versus female is about 3.6–1 which varies from race to race [ 2]. About 50% cases who show anosmia/hyponosmia simultaneously called Kallmann syndrome [ 3]. The Genetic defects are the main underlying mechanism. More than 30 pathogenic genes of CHH have been identified [ 4].
Therapy for CHH depends on the patients’ desire for fertility at the time of treatment. Androgen replacement or sequential therapy of estrogen and progesterone can be used for patients who do not wish to have children. The combination of human chorionic gonadotropin (hCG) and human menopausal gonadotropin (hMG) is used to induce fertility. Pulsatile GnRH is another option for CHH patients who desire a pregnancy.
Nevertheless, the treatment for inducing fertility may not be effective for all CHH patients. Alternate fertility inducing methods have been described for patients who do not respond to hormone replacement therapy (HRT) as HRT replaces lacking hormones rather than inducing ovulation or spermatogenesis. Different assisted reproductive techniques (ART) can improve conception rate. Intrauterine insemination (IUI) is suitable for patients with sexual dysfunction and obstructive fertility. In vitro fertilization-embryo transplantation (IVF-ET) is appropriate for infertility due to many causes, especially the disorder of sperm-egg binding. Intracytoplasmic sperm injection (ICSI) and testicular sperm extraction (TESE) are used for infertility due to decreased quality and quantity of sperms. ART might be an efficient approach to treat infertility in CHH patients due to various causes. The aim of this review was to meta-analyze the pregnancy outcomes in order to reveal the effect of ART on CHH patients, and whether it is distinct from infertility due to other causes.

Methods

This systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) statement [ 5] (Additional file 1: Table S1). Moreover, the analyses were based on previous published studies, thus no ethical approval and patient consent are required according to the regulation of Peking Union Medical College Hospital ethic committee. All previous published studies were approved by ethics committee respectively.

Data sources and searches.

An electronic search of Medline, Embase, and the Cochrane central register of controlled trials was performed. We used keywords and major terms including “hypogonadotropic hypogonadism”, “kallmann syndrome”, “assisted reproductive techniques”, “intrauterine insemination”, “intracytoplasmic sperm injection”, “testicular sperm extraction”, “in vitro fertilization”, “embryo transplantation” and “intra-Fallopian transfer”.
There were no language restrictions, and the retrieval was till March 2018. The detailed search strategies are shown in Additional file 2: Table S2.

Study selection

The included studies were retrospective and researched the positive effect of ART treatment on CHH patients who did not achieve pregnancy after HRT. The inclusion criteria were trials that evaluated at least one of the primary or secondary outcomes mentioned below. The primary outcomes included several pregnancy-related indicators, including fertilization rate, implantation rate, clinical pregnancy per cycle or embryo transfer (ET), and live birth rate. Secondary outcomes included the comparison of pregnancy rates according to different genders, some adverse events arising from ART, such as abortion, multiple gestation and ovarian hyperstimulation syndrome (OHSS). In addition, all the 20 studies we included have clear patient inclusion criteria. The hypophyseal axis was checked by measuring TSH, cortisol, and prolactin, which showed no other combined pituitary hormone deficiency.
Exclusion criteria were [ 1]: klinefelter syndrome [ 2]; adult-onset (secondary) HH [ 3]; reviews and case reports [ 4]; no available end-points; and [ 5] duplications or sub-studies of the included trials.

Data extraction and quality assessment

All studies included in the meta-analysis were reviewed and data on author, year of publication, study design, time, location, number, age and gender of subjects, the duration and methods of HRT, type of surgery and number of cycles were extracted. In addition, fresh/frozen sperm and spouse’s age in males, and body mass index (BMI) in females were observed. The end-points after ART were also extracted for analysis, including fertilization rate, implantation rate, clinical pregnancies, clinical pregnancy per cycle or ET, live birth children, live birth rate and total number of adverse events reported (Table  1).
Table 1
Information of selected studies
Author, year
No.pts
Age mean/SD (year)
BMI mean/SD (kg/m 2)
Treatment, duration
Control group
Type of surgical,
No. of cycles
Fresh/frozen sperm
Spouse’s age (year)
Outcomes (PR, FR, IR) and final outcome (LBR)
Adverse events
Female
 Ulug 2005
58
32.2/5.2
21.09/1.3
HCG, HMG,
TI
IUI, IVF (ICSI)-ET, 53 cycles
n/a
n/a
PR 56.6%,
abortion,
14 days
n = 16
FR 73.9%,
multiple pregnancy
IR 32.4%
 
 Kumbak 2006
27
32.8/4.9
25.7/4.5
gonadotrophins,
UI
IVF (ICSI)-ET,
n/a
n/a
PR 59.3%,
multiple pregnancy
14 days
n = 39
27 cycles
FR 89%,
IR 36.5%
 Yildirim 2010
13
31.3/5.6
25.3/3.1
gonadotrophins,
TI
IVF (ICSI)-ET,
n/a
n/a
PR 80%,
abortion
13 days
n = 20
13 cycles
FR 81.9%,
IR 38.3%,
LBR 50%
 Dokuzeylul 2010
57
≤37
n/a
gonadotrophins,
normal control
IVF (ICSI)-ET,
n/a
n/a
PR 56.14%,
n/a
14 days
n = 95
57 cycles
IR 36.7%
 Caragia 2012
17
32.96/3.976
n/a
FSH, LH,
TI/MI/UI
IVF (ICSI)-ET,
n/a
n/a
PR 55.6%,
no adverse events
16 days
N = 56/56/56
28 cycles
FR 55.4%,
LBR 54%
 Ghaffari 2013
81
33.5/5.3
26.1/4.0
HMG, HCG, P, E2,
TI
IVF (ICSI)-ET,
n/a
n/a
PR 19.4%,
abortion,
14 days
n = 89
72 cycles
FR 61.2%,
multiple pregnancy
IR 40%,
 
LBR 15.2%
 
 Pandurangi 2015
7
27
25.29/3.77
HMG, uFSH,
n/a
IUI, IVF (ICSI)-ET, 19 cycles
n/a
n/a
PR 31.6%,
abortion,
29 days
FR 85%,
multiple pregnancy
LBR 85.7%
 Yilmaz 2015
33
32.5/4.73
26/
3.81
HMG, HCG, recFSH, P,12 days
MI
IVF (ICSI)-ET,
n/a
n/a
PR 30%
n/a
n = 47
33 cycles
 Jiang 2017
46
30.9/3.9
21.26/1.89
HCG, HMG,
TI
IUI, IVF (ICSI)-ET, 42 cycles
n/a
n/a
PR 59.52%,
abortion,
13 days
n = 71
FR 82.13%,
multiple pregnancy
IR 41.46%
 
 Mumusoglu 2017
57
30.6/5.1
25.6/4.5
FSH,
TI
IVF (ICSI)-ET,
n/a
n/a
PR 36.8%,
abortion
11 days
n = 114
57 cycles
IR 34.4%,
LBR 36.8%
 Kuroda 2018
79
32.6/0.5
18/0.3
HCG, HMG,
n/a
IVF (ICSI)-ET,
n/a
n/a
PR 59.3%,
abortion
12.2 days
117 cycles
LBR 45.9%
Male
 Fahmy 2004
15
38.71/6.2
n/a
HCG, HMG,
n/a
TESE+IVF (ICSI)-ET,
n/a
n/a
PR 16.7%,
multiple pregnancy
6 months
17 cycles
FR 41.7%
 Zorn 2005
4
37.75
n/a
HCG, HMG,
n/a
IVF (ICSI)-ET,
fresh/
31.5
PR 33.3%,
no adverse events
13.25 months
9 cycles
frozen sperm
IR 21%
 Bakircioglu 2007
25
34.5/5.2
n/a
HCG,
n/a
TESE+IVF (ICSI)-ET,
fresh/
n/a
PR 54.5%
abortion
9.96 months
22 cycles
frozen sperm
 Akarsu 2009
4
36.25
n/a
HCG, HMG,
n/a
TESE+IVF (ICSI)-ET,
fresh/
29.5
PR 16.7%,
abortion,
9.96 months
18 cycles
frozen sperm
FR 41.8%,
multiple pregnancy
LBR 75%
 
 Resorlu 2009
17
30.1
n/a
HCG, FSH,
n/a
IVF (ICSI)-ET,
fresh
n/a
PR 54.5%
n/a
24 months
11 cycles
sperm
 Dokuzeylul 2010
31
34.82
n/a
HCG, HMG,
n/a
TESE+IVF (ICSI)-ET,
n/a
n/a
PR 51.7%,
abortion,
6 months
29 cycles
FR 83%,
multiple pregnancy
LBR 41.3%
 
 Bakircioglu 2012
12
40.2
n/a
HCG, FSH,
n/a
TESE+IVF (ICSI)-ET,
n/a
n/a
PR 66.7%,
multiple pregnancy
15.3 months
9 cycles
LBR 77.8%
 Sahin 2012
65
n/a
n/a
gonadotrophins,
n/a
IVF (ICSI)-ET,
n/a
n/a
PR 43.9%,
n/a
10.2 months
57 cycles
LBR 60%
 Basar 2017
61
35.8/5.64
n/a
HCG, HMG,
n/a
TESE+IVF (ICSI)-ET,
fresh/
n/a
PR 47.1%,
n/a
n/a
119 cycles
frozen sperm
LBR 62.3%
TI = tubal factor infertility; MI = male factor infertility; UI = unexplained infertility; PR = pregnancy rate; FR = fertilization rate; IR = implantation rate; LBR = live birth rate
Study quality was examined using inclusion and exclusion criteria, definition of end-points, adequacy of follow-up, data analysis and presentation. In addition, studies were scored for quality by Methodological Index for Non-randomized Studies (MINORS). The scores of quality assessment are listed in Table  2. There are eight methodological items for non-randomized studies and four additional criteria for comparative studies. The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global ideal scores are 16 for non-comparative studies and 24 for comparative studies [ 6].
Table 2
Assessment of risk of bias by Methodological Index for Non-randomized Studies (MINORS)
 
1.A clearly stated aim
2.Inclusion of consecutive patients
3.Prospective collection of date
4.Endpoints appropriate to the aim of the study
5.Unbiased assessment of the study endpoint
6.Follow-up period appropriate to the aim of the study
7.Loss to follow up less than 5%
8.Prospective calculation of the study size
9.An adequate control group
10. Contemporary groups
11.Baseline equivalence of groups
12.Adequate statistical analyses
Total
Female
 Ulug (2005)
2
2
2
2
2
0
0
2
2
2
2
2
20
 Kumbak (2006)
2
2
2
2
2
1
0
2
2
2
2
2
21
 Yildirim (2010)
2
0
2
2
2
0
0
2
2
2
2
2
18
 Dokuzeylul (2010)
2
0
2
2
2
0
0
2
2
2
2
2
18
 Caragia (2012)
2
0
1
2
2
0
0
2
2
2
2
2
17
 Ghaffari (2013)
2
2
2
2
2
0
0
2
2
2
2
2
20
 Yilmaz (2015)
2
2
2
2
2
0
0
2
2
2
2
2
20
 Pandurangi (2015)
2
2
2
2
2
0
0
0
0
0
0
0
10
 Jiang (2017)
2
2
2
2
2
0
0
2
2
2
2
2
20
 Mumusoglu (2017)
2
2
2
2
2
0
0
2
2
2
2
2
20
 Kuroda (2018)
2
2
2
2
2
1
0
2
0
0
0
0
13
Male
 Fahmy (2004)
2
2
1
2
2
0
0
0
0
0
0
0
9
 Zorn (2005)
2
1
2
2
2
1
0
0
0
0
0
0
10
 Bakircioglu (2007)
2
1
2
2
2
1
0
0
0
0
0
0
10
 Akarsu (2009)
2
2
2
2
2
0
0
0
0
0
0
0
10
 Resorlu (2009)
2
1
2
2
2
0
0
0
0
0
0
0
9
 Dokuzeylul (2010)
2
0
1
2
2
0
0
0
0
0
0
0
7
 Bakircioglu (2012)
2
1
1
2
2
0
0
0
0
0
0
0
8
 Sahin (2012)
2
1
1
2
2
0
0
0
0
0
0
0
8
 Basar (2017)
2
0
1
2
2
0
0
2
0
0
0
0
9
The items are scored 0 (not reported), 1 (reported but inadequate) or 2 (reported and adequate). The global maximum scores are 16 for non-comparative studies and 24 for comparative studies

Data synthesis and statistical analysis

Data were pooled using a random effects model to obtain a more conservative estimate of ART on CHH patients who were unresponsive or not pregnant after long-term treatment with gonadotropins, allowing for any heterogeneity between studies.
Heterogeneity between studies was assessed using the I 2 statistic with a cut-off of ≥50%, and the X 2 test with a p < 0.10 to define a significant degree of heterogeneity. Where the degree of statistical heterogeneity was greater than this between trial results, possible explanations were investigated using subgroup analysis according to the gender. It can tell the possible reason of heterogeneity. These were exploratory analyses only and may explain some of the observed variability, but the results should be interpreted with caution. The 95% confidence intervals were used to generate Forest plots of pooled relative risks for primary and secondary outcomes. The sample size and risk of bias of included trials is crucial for the weighted differences, which means the more representative study is, the greater the weight is. We also performed a meta-regression analysis by age to show its influence on the pregnancy outcome.

Results

Literature search

The search strategy identified 1030 citations. After eliminating duplicates, 921 studies were subsequently reviewed. The titles and abstracts were screened, and 90 articles were potentially eligible for inclusion. Only 20 of these were retrieved after reading the full-texts. The data in these studies could be consolidated and analyzed (Fig.  1).

Clinical characteristics of patients in the included studies

In the 20 studies included, a total of 475 female CHH patients were included in eleven studies and 234 male CHH patients in the other nine studies. The range of average ages of female CHH patients was 27 to 33.5 years old, and 30.1 to 40.2 years old for male CHH patients. Average BMI of female patients was between 18 to 27 kg/m 2, and no BMI values were described in studies in male patients. Nine out of eleven studies on female CHH patients contained control groups which comprised a total of 659 infertile cases caused by other reasons including tubal factor, male factor or other unexplained factors.

Pregnancy outcomes

The majority treatment regimens used was hCG combined with hMG, duration was around two weeks in females and 6–12 months in males. The type of ART was in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), 3/11 female trials used extra IUI, and 6/9 male trials used TESE. The characteristics of the retrieved trials, including parameters on trial quality, are reported in Tables  1 and 2. A total of 388 pregnancies occurred among 709 individuals who received ART (effectiveness 46, 95% confidence interval 0.39 to 0.53) (Fig.  2). The I 2 in trials assessing overall pregnancy rate (PR) per ET cycle was 73.06%. Similar results were observed in subgroup analysis by sex (Fig.  3). Pregnancy rate was 48% in the female group and 46% in the male group. Meta-regression analysis showed that PR per ET cycle decreased with increasing age (Fig.  4). Sufficient data was not available to evaluate the influence of infertility duration, basal BMI, testis volume or sperm counts and the levels of follicle-stimulating hormone (FSH), leuteinizing hormone (LH) and testosterone (T) on treatment effect of ART.
The forest plots of fertilization rate, implantation rate and live birth rate are shown in Fig.  5. They showed no significant differences as compared to other cohorts.

Adverse events

Individual adverse events were reported in many of the included studies. Fourteen out of 20 trials included abortion rate and 11/20 included the outcomes of multiple pregnancies. Six trials mentioned ovarian hyperstimulation syndrome (OHSS) but there was no OHSS occurrence in the included studies. Only two trials reported ectopic pregnancies. The frequencies of abortion and multiple pregnancies are shown in Fig.  6. There was no statistically significant difference in the incidence of adverse events for CHH patients undergoing ART as compared to infertile cohorts with other causes. Therefore, ART appears to be a safe and effective method to induce fertility in CHH patients.

Discussion

In this study, we systematically reviewed and meta-analyzed pregnancy outcomes in CHH patients undergoing ART. For this specific population, the overall pregnancy rate per ET cycle was about 46% (95% confidence interval 0.39 to 0.53), which was comparable to the patients with other etiological infertility including tubal factor infertility (TI), male factor infertility (MI) and unexplained infertility (UI). The fertilization rate (72%), implantation rate(36%) and live birth rate(51%) were not significantly different from other cohorts. Hence, ART is a viable option for CHH patients with unsuccessful long-term HRT. However, this review had a high risk of potential bias and clinical heterogeneity caused by the study design and the inconsistency in results across the included studies. Factors such as age, BMI, sex hormone levels, pathogenesis of CHH and function of ovary in women, testis volume in men and HRT before ART may have different effects on fertility outcomes in CHH patients treated by ART, and not all these factors were analyzed in the included studies.
Two methods, including hCG combined with hMG and pulsatile GnRH, are common fertility promoting treatments for CHH patients. However, the effectiveness is around 70% [ 7]. About 30% male CHH patients had no or few sperm with conventional therapy (i.e. azoospermia, oligospermia). ICSI combined with TESE may improve their fertility and the pregnancy rates could be similar to those observed in other forms of infertility.
Intra-Fallopian transfer was initially applied for the spouse of a male patient with Kallmann’s syndrome [ 8]. Impaired semen quality prevented his spouse from conceiving and IVF helped the couple in having a healthy baby. Thereafter, some studies presented pregnancies achieved through IVF/ICSI in CHH patients not responding to hormonal treatment [ 9, 10], and pregnancy rates from the large studies were 50–60% [ 11, 12]. Gonadotropin replacement combined with TESE-ICSI cycles improved pregnancy rate of CHH patients [ 13], the clinical pregnancy rate was 17.6%. With the advancement of technology, various ART treatments were applied on CHH patients in different situations such as age, sex, region, duration and extent of illness. The success rate increased to 55% [ 14, 15]. Furthermore, a study in 1997 first emphasized that initiation of ICSI treatment after testicular maturity induced by hormonal treatment contributed to the success of ART [ 16].
Waiting may be advisable as maximal sperm counts are not attained until 12–18 months of treatment, and even longer in cases of cryptorchidism. However, like the general population, chances of fertility in CHH patients after ART reduced with increasing age. Quality and quantity of follicles both decreased. Older women require higher doses of gonadotropins to achieve the desired outcome due to diminished ovarian function with aging [ 12, 17]. Therefore, early ART for unresponsive CHH patients who received HRT for some time may be beneficial.
Multiple pregnancy, abortion, ectopic pregnancy [ 18] and OHSS [ 19] are common adverse events of ART. The multiple pregnancy and abortion rates were around 30% [ 20] and 14.7% [ 21], respectively. These rates did not increase in CHH patients who received ART therapy. Severe OHSS was not observed during ovulation induction in CHH patients [ 11, 22, 23]. The ovaries were dormant and needed to be stimulated with higher doses of gonadotropins, which might theoretically increase the risk of OHSS in the CHH group [ 24], but the frequency of OHSS was not increased in our review.
Several limitations of this meta-analysis should be emphasized. First, the number of included studies was small, which may create selective bias. Second, all included studies were retrospective. Hence, the significant statistical heterogeneities (I 2 = 73.06% in pregnancy rate) may have influenced our findings. Third, the baseline characteristics were not described in detail, which could influence the outcomes by the confounding variables. For example, testis volume and cryptorchidism (maldescended testes) is an important indicator for sperm production, but adequate data was not available for analysis. Great progress in ART treatment also made sense to patients in different decades. Last, it seems that not all studies reported adverse events, and some like OHSS is not considered to be an adverse event, so more studies should be included to avoid the reporting bias.

Conclusions

In summary, the present study showed that despite CHH patients usually being azoospermic, their actual chances of fertility are similar to subjects with other types of obstructive infertility. If CHH patients do not conceive after long-term gonadotropin treatment, ART should be initiated.

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (Grant No. 81771576), National Natural Science Foundation of China (Grant No. 81270879), National Key Research and Development Program of China (2016YFC0905100) and CAMS Innovation Fund for Medical Sciences (2016-I2M-1-002).

Availability of data and materials

The available data and materials section refers to the raw data used in our study are included in manuscript with tables, figures and its supplementary information files. All the authors agreed that the data could be shared if researchers required.

Ethics approval and consent to participate

All analyses were based on previous published studies, thus no ethical approval and patient consent are required according to the regulation of Peking Union Medical College Hospital ethic committee. All previous published studies were approved by ethics committee respectively.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://​creativecommons.​org/​licenses/​by/​4.​0/​), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Zusatzmaterial
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2018

BMC Endocrine Disorders 1/2018 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise